Sanofi disclaims that figure, saying that Viehbacher suggested no such thing during his meeting with Termeer.
赛诺菲方面否认了那个数字,称在与Termeer会谈期间,Viebhacher没有暗示此类事情。
As Henri Termeer, chief executive of Genzyme, a big biotechnology firm, argues, “the blockbuster model becomes less important over time as specialised therapies take off.”
就像大型生物技术公司健赞的首席执行官亨利·特米尔(Henri Termeer)所说,“随着时间的推移,个人化药物的推出,依靠拳头产品的商业模式变得越来越不重要了。”
应用推荐